Effects of microglial interleukin-1β in the pathophysiology of Alzheimer's disease by Val Casals, Maria & Universitat Autònoma de Barcelona. Facultat de Biociències
Introduction 
Effects of Microglial Interleukin-1β in the  
Pathophysiology of Alzheimer’s disease 
 
Maria Val Casals, Autonomous University of Barcelona. Biomedical Sciences Degree 
 
• Scientific literature search on PubMed database: using as keywords 
Microglia + Alzheimer’s Disease + IL-1β or derived combinations. 
Articles cited in articles or reviews were also consulted. Papers were 
sorted by relevance. 
• Alzheimer’s Disease (AD) is a neurodegenerative disorder 
characterized by loss of cognitive function, representing the most 
common cause of dementia in the elderly. 
Methods 
Results 
1.  Microglial response to  Aβ 
Results 
2.  IL-1β effects 
3.  Treatment approaches 
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Fig 2. Microglia around Aβ2 
• Microglia are essential glial cells for 
brain homeostasis. They can be found 
around Aβ (Fig 2) and are able to 
recognize and phagocyte it. The exact 
receptors involved in the process are 
still in debate. 
• They can have different activated phenotypes, being able to secrete 
both anti- and pro- inflammatory proteins (such as IL-1β) depending 
on the context. Mechanisms driving each type of activation are 
poorly understood. 
 
• The NOD-, LRR- and pyrin domain-containing 3 (NLRP3) 
inflammasome is required for caspase-1 activation, which leads to 
maturation of pro-IL-1β to IL-1β. It can be assembled in microglia 
after exposure to Aβ, but the precise mechanisms are also still 
discussed. 
IL-1β activation + 
secretion 
Reported effects of IL-1β on secretases* 
 of different cell lines 
Rat Primary Cortical Neurons α-secretase  ↑ 
APP levels 
unchanged 
Neuroblastoma SK-N-SH +  
Mouse Primary Cortical 
Neurons 
α-secretase  ↑ 
APP levels 
unchanged  
Neuroglioma U251 α-secretase  ↑ 
APP levels ↓ 
HEK293 cells γ-secretase ↑ 
Aβ ↑ 
• First studies in vitro supported that IL-1β increased Aβ 
accumulation and was detrimental for the disease. 
 
• In vivo mice models of IL-1β overexpression (Fig. 3) showed 
that IL-1β decreased Aβ burden. Blocking its expression 
increased Aβ: thus, they support a more physiolgycal role of the 
cytokine. 
 
• IL-1β can increase the expression of certain chemokines, 
which can recruit inflammatory cells from the periphery into 
the brain. Some of those cells contribute to Aβ clearance by 
phagocytosis. 
 
• It has been also proposed that IL-1β could decrease Aβ burden 
in the brain by increasing the activity of non-amyloidogenic 
secretases (α-secretase family). However, the effects found are 
very variable between cell lines.  
* α-secretase precludes Aβ formation; while γ-secretase 
participates in both non- and amyloidogenic APP processing   
Hallmarks of AD 
Parenchymal 
deposition of 
amyloid β (Aβ) 
Neurofibrillary tangles 
(NFT) of 
hyperphosphorylated 
protein tau (pTau) inside 
neurons 
Neuroinflammation 
mainly carried out       
by glial cells 
• The aim of this work is to carry out a review in which:   
• Aβ is formed by secretase 
cleavage from its precursor (APP). 
Its accumulation is supposed to 
trigger the other events in AD.  
 
• Glial response to Aβ could lead 
to:  
Fig 1. Hallmarks of AD1 
Fig 4. Upon binding to its receptor, IL-1β triggers the activation of several pathways 
that can lead to an increase in neurodegeneration via diverse mechanisms4  
• Besides its debatable role in Aβ accumulation, IL-1β has 
other effects that could increase neurodegeneration. 
 
• IL-1β can inhibit Brain Derived Neurotrophic Factor (BDNF) 
signaling, impairing spine formation and synaptic plasticity. 
 
• It can also activate kinases that will phosphorylate protein 
tau. This precedes formation of NFT and neuronal 
dysfunction. 
 
• Moreover, it can increase inducible Nitric Oxide Synthase 
(iNOS) levels, enhancing Nitric Oxide production. This also 
increases oxidative stress, propitiating neurotoxicity. 
 
• In addition, it can induce S100β production in astrocytes. 
This protein can further increase NFT formation,  
neurodegeneration and oxidative stress.  
• Finally, it can 
activate its own 
expression, 
creating a 
neurodegenerative 
cycle, as 
summarized in the 
scheme (Fig 4).  
• Calorie restriction (CR) in rats has been shown to 
decrease IL-1β levels and improve cognitive deficits.  
• CR can also decrease pro-inflammatory cytokines 
in AD mice models, and to reduce the levels of pTau. 
• Anti-IL-R antibodies decreased IL-1β signaling and 
improved cognitive behavior in AD mice models. 
• Aβ immunization showed similar results. 
• Application in patients is controversial due to possible 
side effects. 
• Peptides that shift microglial activation towards an 
anti-inflammatory are being studied.  
• Treatment with non-steroidal anti-inflammatory drugs 
has also been tried, but was less effective than 
expected. 
• Glial cells are actively implicated in the pathogenesis of AD. 
Precise mechanisms are still unclear, but it is by now 
accepted that microglia becomes activated after Aβ 
exposition. They can both phagocyte it and 
secrete proinflammatory proteins in response. 
• A pro-inflammatory state, 
detrimental for the disease  
• Struggle to maintain brain 
homeostasis 
1.  Microglial activation towards Aβ is studied  
2.  Effects of pro-inflammmatory interleukin-1β (IL-1β) are reviewed 
3.  Treatments targeting neuroinflammation are mentioned 
Schematic overview of IL-1β triggered pathways 
• Consensus is needed in the models used: when 
carried out in different models and IL-1β treatment 
conditions, studies generate controversial results. 
Drawing conclusions would be easier if studies were 
carried out in equal conditions and results were 
reproduced.  
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4. Scheme made by the author. 
• More in vivo experiments are lacking to deeply study if IL-1β effects, 
where involvement of other cytokines may interfere. 
 
• New treatments trying to reduce overall neuroinflammation are 
being studied. Translation into applications for real patients must be 
regarded carefully due to possible adverse effects.  
• Initial function of IL-1β is still in debate whilst other, negative 
effects for AD pathogenesis are in a more general agreement. 
